Navigation Links
FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
Date:7/8/2008

WASHINGTON, July 8 /PRNewswire-USNewswire/ -- The following is a statement by Matthew L. Myers, President, Campaign for Tobacco-Free Kids:

The Federal Trade Commission today has taken important action to protect public health by proposing to prohibit tobacco companies from claiming that cigarette tar and nicotine ratings are based on an FTC-approved testing method or that they are endorsed or approved by the FTC. The proposal warns tobacco companies that they risk legal action by the FTC if they use the current tar and nicotine ratings in a way the FTC finds false or misleading. The proposal withdraws an FTC guidance issued in 1966 that permits statements concerning tar and nicotine yields if they are based on a smoking machine test known as the Cambridge Filter Method, commonly called "the FTC method."

While today's FTC action is important, it will not by itself end the tobacco industry's deceptive marketing of "light" and "low-tar" cigarettes and underscores the need for Congress to take comprehensive action by enacting pending legislation to grant the U.S. Food and Drug Administration (FDA) regulatory authority over tobacco products. The FTC's action would not explicitly prohibit the tobacco companies from continuing to make statements regarding tar and nicotine levels and would not immediately ban deceptive cigarette descriptions such as "light" or "low-tar."

The legislation before Congress would ban terms such as "light," "mild" and "low-tar." It would also grant the FDA the authority to strictly regulate any health claims about tobacco products to ensure they are scientifically proven and are not marketed in ways that encourage new smokers to start or discourage current smokers from quitting. The FDA would also have authority to require new testing methods to more accurately measure levels of tar, nicotine and other constituents in tobacco products, to use this information to require changes in tobacco products and to decide whether to publicly release this information. The U.S. House of Representatives is expected to vote on this legislation in the near future.

The FTC's action is necessary in light of the overwhelming scientific evidence that machine-based measures of tar and nicotine do not provide meaningful information about the amounts of tar and nicotine that smokers actually receive or about the relative health risks of different cigarettes. That is because the tobacco industry has been able to design cigarettes to undermine the validity of the test and because the machine test does not take into account the way actual smokers adjust their smoking behavior, for example by taking more or deeper puffs or blocking ventilation holes, to maintain nicotine levels.

Numerous public health authorities, including the National Cancer Institute in a landmark 2001 report, have found that cigarette manufacturers for decades have deceptively marketed "light" and "low-tar" cigarettes as reducing health risks despite knowing from their own research that this was not the case. The manufacturers' ability to claim that nicotine and tar ratings are based on an FTC-approved testing method has been an integral part of this low-tar lie. In an August 2006 ruling that the tobacco companies have violated civil racketeering laws, U.S. District Court Judge Gladys Kessler found that the tobacco company defendants "falsely marketed and promoted 'low tar' and 'light' cigarettes as less harmful than full-flavor cigarettes in order to keep people smoking and sustain corporate revenues."

Today's FTC action also provides important support for ongoing litigation to hold cigarette manufacturers accountable for the harm caused by their deceptive marketing of "light" and "low-tar" cigarettes. Class-action lawsuits have been filed in several state courts accusing cigarette manufacturers of fraudulently marketing "light" and "low-tar" cigarettes as safer than other cigarettes. The Altria Group Inc., parent company of Philip Morris, has asked the U.S. Supreme Court in a pending appeal to dismiss the state cases because the company acted on the basis of FTC regulation that preempts state law. The FTC and the U.S. Solicitor General last month filed a brief in the case urging the Supreme Court to reject Altria's appeal. The brief argued that the FTC "never gave affirmative endorsement to such descriptors, much less to their deceptive use."

More information on the FTC's action is available at http://www.ftc.gov/opa/2008/07/cigarettefyi.shtm.


'/>"/>
SOURCE Campaign for Tobacco-Free Kids
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Antidepressants in suicide prevention
2. Dietary Supplement May Prevent Breast Cancer
3. Aggressive treatment of childhood eczema could help prevent asthma, says new study
4. Topical oral syrup prevents early childhood caries
5. Lots of Sex May Prevent Erectile Dysfunction
6. Glaucoma Treatment Can Prevent Blindness
7. Texas Oncology Urges Texans to ‘Save Your Skin:' Outsmart the Sun and Prevent Skin Cancer
8. Glaucoma procedure now available at Mayo Clinic aims to prevent further eye damage
9. Pediatrics review of underage drinking prevention programs led by Iowa State researcher
10. Oral Drug Helps Prevent Clotting After Hip Replacement
11. Study further defines potential role of fish-based fatty acids in resolving, preventing asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... use disorder, but concern for women who become dependent on opioid painkillers has fallen ... among female patients, compared to a 237% increase in fatal overdoses in male populations.(1) ...
(Date:2/27/2017)... ... ... Orange County dentist, Dr. A. Rassouli, comments on the new ... bacteria in plaque infect the gums and other tissues supporting the teeth. Treatment typically ... SRP, and can include surgical therapies if the condition has led to significant damage. ...
(Date:2/27/2017)... ... ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and Associated ... Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss any ... into a single volume a compelling argument that the disease does exist in his ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... center for hair transplantation therapy, is proud to announce a new informational post ... hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017   Royal Philips (NYSE: ... in health technology, today announced 510(k) clearance from ... market its ElastQ Imaging capability, further expanding the ... ElastQ Imaging enables simultaneous imaging of tissue and ... the diagnosis of various liver conditions. With ElastQ ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... , Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) ... Adam Craig , M.D., Ph.D., as President and Chief Executive ... March 20, 2017. Dr. Craig succeeds Richard Love , ... the company,s Board of Directors.  Dr. Craig has over 20 ... both the US and Europe . ...
Breaking Medicine Technology: